MXPA02005626A - Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente. - Google Patents

Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.

Info

Publication number
MXPA02005626A
MXPA02005626A MXPA02005626A MXPA02005626A MXPA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A
Authority
MX
Mexico
Prior art keywords
osteoporosis
ductus arteriosus
compositions
glomerular filtration
patent ductus
Prior art date
Application number
MXPA02005626A
Other languages
English (en)
Inventor
Krishna G Peri
Original Assignee
Pital Sainte Justine H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pital Sainte Justine H filed Critical Pital Sainte Justine H
Publication of MXPA02005626A publication Critical patent/MXPA02005626A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Water Treatment By Sorption (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Pipe Accessories (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Joints With Sleeves (AREA)

Abstract

La presente invencion se refiere a una composicion de una materia que comprende antagonistas novedosos del receptor de prostaglandina E2, y su uso en tratamientos para regular la filtracion de fluidos en el rinon, evitando la perdida mineral de los huesos en la osteoporosis y la enfermedad dental y adicionalmente, el cierre de los conductos arteriosos (DA) en infantes prematuros o animales fetales. Adicionalmente, las composiciones incluyen peptidos lineales, analogos peptidos, y peptidomimeticos.
MXPA02005626A 1999-12-06 2000-12-06 Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente. MXPA02005626A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45548399A 1999-12-06 1999-12-06
PCT/CA2000/001445 WO2001042281A1 (en) 1999-12-06 2000-12-06 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Publications (1)

Publication Number Publication Date
MXPA02005626A true MXPA02005626A (es) 2004-09-10

Family

ID=23808998

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005626A MXPA02005626A (es) 1999-12-06 2000-12-06 Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.

Country Status (12)

Country Link
US (1) US7442763B2 (es)
EP (1) EP1244693B1 (es)
JP (1) JP2003516417A (es)
AT (1) ATE298346T1 (es)
AU (1) AU784630B2 (es)
CA (1) CA2396739A1 (es)
DE (1) DE60020997T2 (es)
ES (1) ES2246915T3 (es)
MX (1) MXPA02005626A (es)
NZ (1) NZ520762A (es)
WO (1) WO2001042281A1 (es)
ZA (1) ZA200205795B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
WO2001042281A1 (en) 1999-12-06 2001-06-14 Hôpital Sainte-Justine Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis
WO2003030911A1 (en) * 2001-10-08 2003-04-17 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
ES2292814T3 (es) * 2001-10-31 2008-03-16 Medical Research Council Antagonistas de los receptores ep2 y/o ep4 de la prostaglandina para el tratamiento de la menorragia.
WO2003099857A1 (en) * 2002-05-23 2003-12-04 Theratechnologies Inc. Antagonistic peptides of prostaglandin e2 receptor subtype ep4
EP1878741A3 (en) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
US7414029B2 (en) 2002-05-23 2008-08-19 Theratechnologies, Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
WO2013167582A1 (en) 2012-05-09 2013-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
AU4855393A (en) 1992-09-10 1994-03-29 New York University Polypeptides of g-coupled receptor proteins, and compositions and methods thereof
ATE466869T1 (de) * 1993-03-05 2010-05-15 Epimmune Inc Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden
US5869281A (en) 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
US5605814A (en) 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
JPH09504174A (ja) * 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
JPH10505481A (ja) * 1994-04-22 1998-06-02 アメリカ合衆国 メラノーマ抗原
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
WO1996006856A1 (en) * 1994-08-31 1996-03-07 Robert Webber Dopamine receptor peptides and anti-peptide antibodies
EP1609477B1 (en) * 1994-12-12 2011-11-09 Omeros Corporation Irrigation solution and use thereof for the perioperative inhibition of pain/inflammation and/or spasm at a vascular structure
EP0870198A4 (en) 1995-01-25 2001-04-04 Cor Therapeutics Inc RECOMBINANT C140 RECEPTOR, ITS AGONISTS AND ANTAGONISTS, AND NUCLEIC ACIDS ENCODING THE RECEPTOR
US5877155A (en) * 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
US6117839A (en) * 1995-06-07 2000-09-12 Gensci Regeneration Sciences, Inc. Bone stimulating factor
EP0907370B1 (en) * 1996-03-21 2005-05-25 Epimmune Inc. Hla-a2.1 binding peptides and their uses
AU715632B2 (en) * 1996-09-12 2000-02-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5955575A (en) 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
AUPP320998A0 (en) * 1998-04-27 1998-05-21 Walter And Eliza Hall Institute Of Medical Research, The Tyrosine phosphatase IA-2 T-cell epitopes
US6984719B1 (en) 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US20040235749A1 (en) 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
WO2001042281A1 (en) 1999-12-06 2001-06-14 Hôpital Sainte-Justine Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Also Published As

Publication number Publication date
EP1244693A1 (en) 2002-10-02
CA2396739A1 (en) 2001-06-14
DE60020997T2 (de) 2006-05-24
US7442763B2 (en) 2008-10-28
DE60020997D1 (de) 2005-07-28
AU784630B2 (en) 2006-05-18
ATE298346T1 (de) 2005-07-15
EP1244693B1 (en) 2005-06-22
NZ520762A (en) 2005-02-25
ES2246915T3 (es) 2006-03-01
JP2003516417A (ja) 2003-05-13
WO2001042281A1 (en) 2001-06-14
ZA200205795B (en) 2007-01-31
AU2134001A (en) 2001-06-18
US20030017988A1 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
MXPA02005626A (es) Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.
KR101956579B1 (ko) 상아질 지각과민증 완화를 위한 치약 조성물
CA1315480C (en) Phosphopeptides
PT861261E (pt) Sequências nucleotídicas e proteicas de genes delta de vertebrado e métodos nelas baseados
YU53502A (sh) Blokada aksonalnog rasta posredstvom nogo receptora
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
BR0115687A (pt) Agonistas seletivos do receptor ep4 no tratamento de osteoporose
AU1153902A (en) Nogo receptor homologs
AP2000001905A0 (en) Peptide compositions and formulations and use of same.
DK0664133T3 (da) "Ostim Apatit"-præparat til stimulering af vækst i knoglevæv
IL146009A0 (en) Stereoselective antifibrillogenic peptides and peptidomimetics thereof
PL329526A1 (en) Casein peptide containing tooth-cleaning composition of long shelf-life
AP9801269A0 (en) Prostaglandin agonists.
HK1041449B (zh) 可在體內減少α2-抗纖溶酶的化合物在製備用於治療局部缺血性中風的組合物中的用途
GB0110430D0 (en) Protein variants and uses thereof
AU8326801A (en) Dental products comprising bone growth enhancing peptide
BR112019018871A2 (pt) complexos para tratar sensibilidade
KR20210139321A (ko) 광화를 촉진하기 위한 조성물 및 방법
MX2007000120A (es) Composicion herbacea.
HK1041633A1 (en) Composition and use of rar antagonists for promoting chondrogenesis
HK1053053A1 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies.
IL143956A (en) Chimeric polypeptide having the antigenic determinants of four proteins of l. infantum, polynucleotides encoding same, methods of production and use thereof in therapeutic compositions
AU2003251729A1 (en) Use of antibodies against flt-1 for the treatment of osteoporosis
DE60232140D1 (de) Zusammensetzung zur prävention und/oder behandlung von verändertem knochenmetabolismus